AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments
Almost two years after first inking a deal with AbbVie worth $100 million upfront, Morphic Therapeutic received another bit of good news from the pharma giant.
The biotech announced Tuesday morning that AbbVie has exercised a licensing option as part of that 2018 agreement, giving the pharma exclusive rights to two integrin inhibitors programs for idiopathic pulmonary fibrosis and other fibrosis-related diseases. Morphic will receive a $20 million licensing fee with potential future milestone payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.